Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: Anti-VEGF, Hemorrhage displacement + Anti-VEGF; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: SCD411, Aflibercept; Drug
Lead sponsor: Sam Chun Dang Pharm. Co. Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more

Conditions: Age-Related Macular Degeneration
Interventions: Intravitreal aflibercept injection, Placebo; Drug
Lead sponsor: Jeffrey S Heier; Other
Eligibility: Not listed
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more

Conditions: Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 5 Years to 85 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cystoid Macular Edema,, Retinal Thickening
Interventions: 2. Xibrom (Bromfenac), 1. Pred Forte; Drug
Lead sponsor: Center For Excellence In Eye Care; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Retinoblastoma
Interventions: Skin Biopsy, Blood Draw; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization, Genetic Counseling
Interventions: Early disclosure, Late disclosure; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Refractive Error, Cataract, Maculopathy
Interventions: Not listed
Lead sponsor: Sinclair Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Elkins Park, Pennsylvania

Conditions: Diabetic Retinopathy
Interventions: PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham; Drug
Lead sponsor: Perfuse Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Interventions: Not listed
Lead sponsor: Alcon Research; Industry
Eligibility: 55 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Retinoblastoma
Interventions: Melphalan hydrochloride; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: becatecarin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 198
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more

Conditions: Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia
Interventions: Retinal fundus photography; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Interventions: observational study, VOY-101; Other · Biological
Lead sponsor: Perceive Biotherapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah

Conditions: Leber Hereditary Optic Neuropathy
Interventions: GS010, Placebo; Genetic · Drug
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Pasadena, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions: AMDX2011P; Drug
Lead sponsor: Amydis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Newport Beach, California • Pasadena, California

Conditions: Choroideremia
Interventions: Observation; Other
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • Salt Lake City, Utah

Conditions: Macular Degeneration
Interventions: Video camera magnifier; Behavioral
Lead sponsor: Mary Lou Jackson; Other
Eligibility: 40 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinopathy of Prematurity
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 32 Weeks to 40 Weeks
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 11
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more

Conditions: Geographic Atrophy
Interventions: ORACEA®, Placebo; Drug
Lead sponsor: Paul Yates, MD, PhD; Other
Eligibility: 55 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 37
States / cities: Glendale, California • Poway, California • Golden, Colorado + 31 more

Conditions: Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinal Neovascularization
Interventions: Not listed
Lead sponsor: Notal Vision Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • St Louis, Missouri

Search by objective public record fields.

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD

Vision Measured by the Vimetrics CVA Compared With Chart Testing Under Similar Luminance and Contrast Conditions

A Study of PER-001 in Participants With Diabetic Retinopathy

The Natural History of Geographic Atrophy Progression (GAP) Study

OCT Biomarkers for Diabetic Retinopathy

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

"Natural History" Study of Choroideremia

Reading Performance With a Video Magnifier

Telemedicine Approaches to Evaluating Acute-phase ROP

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.